• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction.
【24h】

Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction.

机译：在勃起功能障碍的PDE5抑制剂无反应者中，结合使用真空勃起装置和PDE5抑制剂作为挽救疗法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Oral phosphodiesterase type 5 inhibitors (PDE5i) have improved treatment options for erectile dysfunction (ED). In case of unresponsiveness to PDE5i, alternative therapies are considered. AIM: To evaluate whether combination of vacuum erection device (VED) and PDE5i is effective as salvage therapy in subjects with ED in whom PDE5i alone failed. METHODS: From September 2007 to May 2008, we evaluated 69 men (aged 36-82 years) in whom PDE5i treatment at the highest recommended dose, with at least 4-6 attempts at intercourse during a 3 months period, had failed. The clinical efficacy of combination therapy was evaluated using the International Index of Erectile Function-5 (IIEF-5) questionnaire, Sexual Encounter Profile (SEP)-2, SEP-3, and Global Patient Assessment Scale (GPAS). MAIN OUTCOME MEASURES: Scores on IIEF-5, SEP-2, SEP-3, and GPAS before and after combination therapy were measured. RESULTS: After 4 weeks of combination therapy, the mean IIEF-5 score increased significantly over baseline from 9.0 to 17.6 (P < 0.001). Of the 34 subjects with a SEP-2 response of "no" at baseline, 27 (79%) responded "yes" after combination therapy (P < 0.001). Of the 50 subjects with a SEP-3 response of "no" at baseline, 35 (70%) responded "yes" after combination therapy (P < 0.001). Furthermore, of the 42 subjects with a GPAS response of "not at all" or "slightly" improved at baseline, 31 (74%) responded "moderately" or "greatly" improved after combination therapy (P < 0.001). One subject (1.5%) experienced device-related intermittent penile pain, which resolved after 4 days without any action. CONCLUSIONS: Statistically significant improvements over baseline were seen in IIEF-5, SEP-2, SEP-3, and GPAS measures following 4 weeks of combination therapy of PDE5i and VED. This study supports the use of PDE5i with VED in men in whom PDE5i alone failed. This combination therapy may be offered to patients not satisfied with PDE5i alone before being switched to more invasive alternatives.
机译：简介：口服磷酸二酯酶5型抑制剂（PDE5i）具有改善的勃起功能障碍（ED）治疗选择。如果对PDE5i无反应，可以考虑采用其他疗法。目的：评估真空勃起装置（VED）和PDE5i的组合在单独使用PDE5i失败的ED患者中作为挽救疗法是否有效。方法：从2007年9月至2008年5月，我们评估了69名男性（年龄36-82岁），他们在最高推荐剂量下进行PDE5i治疗，并在3个月内进行了至少4-6次性交尝试。使用国际勃起功能指数5（IIEF-5）问卷，性遭遇概况（SEP）-2，SEP-3和全球患者评估量表（GPAS）评估联合治疗的临床疗效。主要观察指标：测量联合治疗前后IIEF-5，SEP-2，SEP-3和GPAS的得分。结果：联合治疗4周后，IIEF-5的平均得分比基线从9.0显着提高到17.6（P <0.001）。在基线时SEP-2反应为“否”的34位受试者中，有27位（79％）在联合治疗后反应为“是”（P <0.001）。在基线时SEP-3应答为“否”的50名受试者中，有35名（70％）在联合治疗后应答为“是”（P <0.001）。此外，在基线时GPAS反应“根本没有”或“轻微”改善的42位受试者中，有31位（74％）在联合治疗后反应“中等”或“大大”改善（P <0.001）。一名受试者（1.5％）经历了与设备有关的间歇性阴茎疼痛，该疼痛在4天后无任何缓解。结论：PDE5i和VED联合治疗4周后，IIEF-5，SEP-2，SEP-3和GPAS措施在基线上有统计学上的显着改善。这项研究支持将PDE5i与VED一起用于仅PDE5i失败的男性。可以将这种联合疗法提供给对PDE5i不满意的患者，然后再改用更具侵入性的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号